We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...
Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for ...
According to ZERO Prostate Cancer, Novartis has committed $7.5 million to the initiative.
Unlike other brands that release their ads days or weeks ahead of the Big Game, Novartis is waiting to unveil its commercial during the contest.
Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...
Prior to this announcement, Novartis' dividend was comfortably covered by both cash flow and earnings. This indicates that ...
Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...
Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...
Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...
The campaign is based on the results of a survey that reveals the experiences of patients and caregivers in their communities ...
Novartis Indias NEST competition culminates in a showcase of innovative healthcare solutions, highlighting the talent of young entrepreneurs.
Swiss pharma giant Novartis is taking legal action against the Australian cancer care provider as a dispute over how to fund ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback